New Combination Drug for Depression : AJN The American Journal of Nursing

You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.

Drug Watch

Aschenbrenner, Diane S. MS, RN

Author Information

Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch: [email protected].

AJN, American Journal of Nursing | DOI: 10.1097/01.NAJ.0000925488.72453.63 Metrics Abstract Auvelity, an extended-release fixed combination of dextromethorphan and bupropion, is approved for the treatment of major depressive disorder in adults. Like all antidepressants, dextromethorphan–bupropion carries a boxed warning that it may increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Seizures can also occur and are more likely at higher doses. The most common adverse effects of dextromethorphan–bupropion include dizziness, nausea, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, hyperhidrosis, anxiety, constipation, decreased appetite, and insomnia. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. Full Text Access for Subscribers:

You can read the full text of this article if you:

Select an optionLog InBuy ArticleSubscribeContent & PermissionsAccess through Ovid

Log In Access through Ovid Article Level Metrics Readers Of this Article Also Read